27.11.2012

After license deal for letermovir: Head-to-head phase 2 trial initiated by AiCuris to demonstrate superiority of its novel drug pritelivir vs. valacyclovir for treatment of genital herpes

more...

15.10.2012

Aicuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus

more...

07.08.2012

AiCuris promising drugs against Herpes simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in preparation for phase III:

more...

16.04.2012

Better prevention of transmission and lesion development of genital herpes predicted for AiCuris drug AIC316 Data showing stronger reduction of clinically relevant viral shedding in comparison with nucleosides to be presented at upcoming conferences

more...

02.04.2012

Results of Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants meeting both primary Efficacy Endpoints to be presented at International Conferences

more...

14.02.2012

AiCuris Drug Letermovir (AIC246) meets primary efficacy endpoints in phase 2 for human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell recipients

more...

05.01.2012

AiCuris receives Orphan Drug Designation for Letermovir (AIC246) from FDA

more...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
Management Assistant

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com